ClinicalTrials.gov
public full text
Public Domain
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants#980134
- Quality of Life and Neurocognitive Functioning#1010025
- Clinical Evaluation for Digital Acupuncture Manipulation Therapeutic Instrument#1087805
- Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002#1031110
- RECaST-Surv: A Calibrated Borrowing Method for Survival Endpoints in Unequal Randomized Trials#1013316
Record · ID 855740
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive